Skip Ribbon Commands
Skip to main content

Trials open for cancer patients

Cancer patients are often invited to participate in trials and studies to improve treatments and cancer drugs. The table below lists all ongoing treatment and clinical drug trials open for cancer patients in our hospital.  

If you are interested in participating in any one of the trials, please contact the unit where you are being treated for further advice.

You can promote the scientific study of cancer and health if you consent to providing the hospital with blood or tissue samples taken as you are being treated for deposition in the hospital's biobank. You may obtain more information and download the consent form here.


Gynaecological cancers

​A randomized, double-blind, phase 3 comparison of platinum-based therapy with tsr-042 and niraparib versus standard of care platinum-based therapy as first-line treatment of stage III or IV nonmucinous epithelial ovarian cancer.

A phase III, multicenter, randomized, study of atezolitzumab versus placebo administered in combination with paclitaxel, carboplatin and bevacizumab to patients with newly-diagnosed stage III or stage IV ovarian, fallopian tube or primary peritoneal cancer

ENGOT-EN2-DGCGRandomized multicenter trial on the risk of recurrence for patients with cancer limited to the uterus. After surgery, adjuvant treatment or follow-up.

Paediatric cancers
NOPHO-DBH-AML2012​ Phase III study for treatment of children and adolescents with acute myeloid leukaemia 0-18 years
IntreALL 2010SR​International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010. A randomized Phase III Study Conducted by theResistant Disease Committee of the International BFM Study Group
SIOP PNET 5-MBAn international prospective study on clinically standard-risk meduloblastoma in children older than 3 to 5 years with low-risk biological profile (PNET 5 MB-LR) or average-risk biological profile
EURO-Ewing-2008A randomised trial for patients with localised or metastatic Ewing sarcomas
Einstein 14372Multicenter, open-label, active-controlled, randomized study to evaluate the efficacy and safety of an age-and body weight-adjusted rivaroxaban regimen compared to standard of care in children with acute venous thromboembolism. EINSTEIN Junior Phase III: oral rivaroxaban in children with venous thrombosis

NOPHO ALL2008​Treatment Protocol for Children (1.0 - 17.9 years of age) and young adults (18-45 years of age) with Acute Lymphoblastic Leukemia.

​Radiotherapy Delivery in Deep Inspiration for Paediatric Patients- A feasibility study

​SAKK 35/14
​Rituximab with or without ibrutinib for untreated patients with advanced follicular lymphoma in need of therapy.

Chronos-4A phase III,double-blind,controlled,multicenter study of intravenous PI3K inhibitor copanlisib in combination with standard immunochemotherapy versus standard immunochemotherapy in patients with relapsed indolent non-Hodgkin's lymphoma (iNHL)
Bio-CHICBiomarker Driven and Dose Intensified Chemoimmunotherapy With Early CNS Prophylaxis in Patients Less Than 65 Years With High Risk Diffuse Large B-Cell Lymphoma
Breast cancer
​BOLDA randomized phase III study comparing trastuzumab,pertuzumab plus docetaxel (TPD) followed by 3 cycles of chemotherapy to the current standard regimen as the treatments of early HER2-positive breast cancer

​Moderately hypofractionated logo-regional adjuvant radiation therapy of early breast cancer combined with a simultaneous integrated boost in patients with an indication for boost

​AdeLE (Herantis)
​A phase II, double-blind, placebo-controlled, randomized study to assess the efficacy, safety and tolerability of Lymfactin (AdAptVEGF-C Adenoviral Vector) in combination with a surgical lymph node transfer for the treatment of patients with secondary lymphedema associated with the treatment of breast cancer.
​MO39193​A phase III, randomized, double-blind, placebo-controlled, multicentre study of the efficacy and safety of atezolizumab plus chemotherapy for patients with early relapsing recurrent triple-negative breast cancer.
Urological cancers

KEYNOTE-057Open clinical trial to assess the efficacy and safety of pembrolizumab (MK-3475) in the treatment of patients with cancer of the superficial layer of the urinary bladder and in whom treatment with BCG (Bacillus Calmette Guerin) is no longer efficacious or who do not tolerate such treatment

FINNBLADDER 9Treatment of stage Ta cancer of the urinary bladder with a high risk of relapse – blue-light cystoscopy and optimized dosage of mitomycin-C.

​Intravesical Instillation Therapy With Bacillus Calmette-Guérin (BCG) and Sequential BCG and Electromotive Mitomycin-C (EMDA-MCC) in Patients With High-risk Non-muscle-invasive Bladder Carcinoma.

SPCG-15Surgery or radiation therapy in the treatment of locally advanced prostate cancer – open, randomized clinical trial.

​A prospective single-institutional study comparing the diagnostic accuracy of novel imaging modalities to traditional imaging modalities among high risk prostate cancer patients at initial diagnosis.

​A early phase 1 non-randomized prospective single-institutional and four arm study to determine the applicability, feasibility and safety of MRI guided transurethral HIFU ablation of prostate separately in each pre-specified group/arm.

​A phase 3, randomized, double-blind, placebo-controlled study of talazoparib with enzalutamide in metastatic castration-resistant prostate cancer.
Head and neck cancers
POET-HNSProspective multiregister study on the incidence of perioperative cardiovascular events and haemorrhages in association with surgery for head and neck cancer.  Safety and effects of aspirin on perioperative bleeding.
Haematological cancer

​A Prospective, Multicenter, Phase-II Trial of Ibrutinib Plus Venetoclax in Patients With Creatinine Clearance >= 30 ml/Min Who Have Relapsed or Refractory Chronic Lymphocytic Leukemia (RR-CLL) With or Without TP53 Aberrations

​A phase 3 multicenter, randomized, prospective, open-label trial of standard chemoimmunotherapy (FCR/BR) versus rituximab plus venetoclax (RVe) versus obinutuzumab (GA101) plus venetoclax (GVe) versus obinutuzumab plus ibrutinib plus venetoclax (GIVe) in fit patients with previously untreated chronic lymphocytic leukemia (CLL) without del(17p) or TP53 mutation.
Päivitetty: 12/11/2019 13:07